[PD-L1 status in breast cancer].
| Autor: | Frank GA; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia., Kuznetsova OA; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia., Zavalishina LE; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia., Andreeva YY; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia., Olyushina EM; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia., Vinogradov IY; Regional Clinical Oncology Dispensary, Ryazan, Russia., Vinogradov MI; Ryazan State Medical University, Ministry of Health of Russia, Ryazan, Russia., Kulikov EP; Ryazan State Medical University, Ministry of Health of Russia, Ryazan, Russia., Shomova MV; Regional Clinical Oncology Dispensary, Ryazan, Russia. |
|---|---|
| Jazyk: | ruština |
| Zdroj: | Arkhiv patologii [Arkh Patol] 2019; Vol. 81 (2), pp. 3-9. |
| DOI: | 10.17116/patol2019810213 |
| Abstrakt: | Objective: To investigate the expression of PD-L1 in triple-negative and luminal B, HER2-negative breast carcinoma and to assess the association of the tumor PD-L1 status with the prognosis of the disease. Subject and Methods: The PD-L1-status of primary tumor was studied in 72 patients with breast cancer, by using an immunohistochemical method. Results: Differences were found in the incidence of carcinomas with PD-L1 expression in tumor cells depending on the molecular genetic type: there was a positive PD-L1 status in luminal B, HER2-negative tumors in 4 (14.81%) of 27 cases and in triple-negative tumors in 17 (37.78%) of 45 cases. An analysis of tumors after neoadjuvant therapy revealed a positive PD-L1-status in tumor cells in 1 of 18 patients with a moderate residual tumor load and in 6 of 13 with a high residual tumor load (5.56 and 46.15%, respectively), as estimated by the RCB system. Conclusion: The positive PD-L1 status in triple-negative breast cancer was determined more than 2 times as frequently as in luminal B, HER2-negative breast cancer (37.78 and 14.81%). There was a considerable correlation between the high residual tumor load and the positive tumor PD-L1 status. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|